Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064848 | 0.75 | SMN1; SMN2 (0.52) | METAP2METAP1SMN1; SMN2NPY5RENPP1 | |
| SCHEMBL2011131 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL357003 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL3894 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL375955 | 0.75 | SMN1; SMN2 (0.52) | METAP2METAP1SMN1; SMN2NPY5RENPP1 | |
| SCHEMBL7787137 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL5632 | 0.75 | NUDT1 (0.50) | METAP2METAP1NPY5R | |
| SCHEMBL3801779 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL277596 | 0.75 | METAP2 (0.51) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL30388675 | 0.75 | NUDT1 (0.50) | METAP2METAP1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017097973-A1 | MODIFIED NUCLEOSIDES | UNIVERSITAET KONSTANZ (DE) | 2017-06-15 | — | — | WO | claimed |
| CN-103068834-B | Phosphoramidites for reverse RNA synthesis | 坎姆根公司 | 2016-10-26 | — | — | CN | claimed |
| US-8541569-B2 | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA | CHEMGENES CORPORATION (US) | 2013-09-24 | — | — | US | claimed |
| CN-103068834-A | Phosphoramidites for reverse RNA synthesis | CHEMGENES CORP | 2013-04-24 | — | — | CN | claimed |
| EP-2560982-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | Chemgenes Corporation (US) | 2013-02-27 | — | — | EP | claimed |
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION | 2012-06-14 | — | — | US | claimed |
| EP-2398815-A2 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | Chemgenes Corporation (US) | 2011-12-28 | — | — | EP | claimed |
| WO-2011103468-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | CHEMGENES CORPORATION (US) | 2011-08-25 | — | — | WO | claimed |
| US-20110137010-A1 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA | CHEMGENES CORPORATION (US) | 2011-06-09 | — | — | US | claimed |
| WO-2010096201-A2 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION (US) | 2010-08-26 | — | — | WO | claimed |
| EP-1383925-A2 | METHOD FOR LABELLING AND FRAGMENTING DNA | BIO MERIEUX (FR) | 2004-01-28 | — | — | EP | claimed |
| US-20030143555-A1 | Fragmenting the DNA by creating at least one abasic site on DNA, attaching a marker to one of the fragments by means of labeling reagent which is covalently and predominantly coupling to the phosphate of the fragment | BIO MERIEUX (FR) | 2003-07-31 | — | — | US | claimed |
| WO-2002090584-A2 | METHOD FOR LABELLING AND FRAGMENTING DNA | BIO MERIEUX (FR) | 2002-11-14 | — | — | WO | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| CN-1068111-A | (mixing) aryl oxide and sulfide derivative, its preparation method and pharmaceutical composition | PERREL S P A (IT) | 1993-01-20 | — | — | CN | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
| EP-0175325-B1 | NEW 8-SUBSTITUTED NUCLEOSIDE AND PURINE DERIVATIVES, THE PROCESS FOR THE PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pierrel S.p.A. (IT) | 1989-03-15 | — | — | EP | claimed |
| CN-85108905-A | Process for the preparation of 8-substituted nucleosides and purine derivatives and their use | — | 1987-06-24 | — | — | CN | claimed |
| EP-0175325-A2 | New 8-substituted nucleoside and purine derivatives, the process for the preparation thereof and the pharmaceutical compositions containing them | Pierrel S.p.A. (IT) | 1986-03-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | TYMP, MTAP, GART | METAP2 821/4885METAP1 859/4885ADORA2A 170/4885 |
| US-20110137010-A1 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA | NSUN3, RNGTT, NOP2 | METAP2 2164/4885METAP1 1674/4885ADORA2A 1238/4885 |
| US-20030143555-A1 | Fragmenting the DNA by creating at least one abasic site on DNA, attaching a marker to one of the fragments by means of labeling reagent which is covalently and predominantly coupling to the phosphate of the fragment | FEN1, DNMT1, UNG | METAP2 648/4885METAP1 873/4885ADORA2A 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.